GlassScriptPhysician profile
Lisa Pennington
NPI 1710968557
$7,236.82
in general payments reported to CMS, 2019-2025
30 companies · $2,239 in 2025
The $2,239 reported for 2025 was more than what 92% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $953 · 2022: $944 · 2023: $1,437 · 2024: $1,665 · 2025: $2,239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,340.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,340.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,320.32 | 2021-2025 | |
| Glaxosmithkline, LLC. | $1,061.57 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Pfizer INC. | $864.89 | 2021-2025 | |
| Lilly USA, LLC | $727.79 | 2021-2025 | Mounjaro, Zepbound, Emgality |
| Novo Nordisk INC | $651.06 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $499.31 | 2022-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $383.99 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $297.93 | 2021-2025 | Jardiance, Synjardy |
| Amgen INC. | $156.46 | 2024-2025 | Otezla, Repatha, Otezla |
| Abbott Laboratories | $143.50 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Biohaven Pharmaceutical Holding Company LTD. | $129.22 | 2022 | |
| Novartis Pharmaceuticals Corporation | $108.92 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $105.20 | 2021-2024 | Verquvo, Belsomra, Steglatro |
| Exact Sciences Corporation | $102.83 | 2023-2025 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $86.80 | 2025 | Caplyta |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $86.29 | 2021-2025 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $76.32 | 2025 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $75.48 | 2021 | |
| Axsome Therapeutics, INC. | $60.58 | 2023-2025 | Auvelity, Sunosi |
| Corcept Therapeutics | $41.95 | 2025 | Korlym |
| Verona Pharma, INC. | $41.48 | 2025 | Ohtuvayre |
| Phathom Pharmaceuticals, INC. | $35.26 | 2024 | Voquezna |
| Evoke Pharma, INC. | $33.05 | 2023 | Gimoti |
| Currax Pharmaceuticals LLC | $30.94 | 2022-2025 | Contrave |
| Ars Pharmaceuticals Operations, INC. | $24.08 | 2025 | Neffy |
| Daiichi Sankyo INC. | $22.91 | 2023 | Injectafer |
| Lundbeck LLC | $18.94 | 2025 | Rexulti |
| Astellas Pharma US INC | $17.44 | 2022 | |
| Amarin Pharma, INC. | $16.40 | 2021 | |
| Vanda Pharmaceuticals INC. | $15.91 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Pennington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.